Vitamin D deficiency affects roughly two in five American adults. The standard response for decades has been a daily oral supplement. In June 2026 a Bainbridge Island startup called Solius Labs launched something different: the first FDA-cleared, over-the-counter UVB light panel specifically designed to stimulate the body’s own production of vitamin D. To make that clearance possible, the agency had to create an entirely new product code.

Long before vitamin D became a mainstream talking point, it was already a quiet obsession in certain elite and integrative-medicine circles. In 2009, Beverly Hills physician Dr. Soram Khalsa published The Vitamin D Revolution, a book that distilled emerging research linking deficiency to everything from immune resilience to chronic disease risk and made the case for routinely testing and optimizing levels. Drawing on years of clinical observation in his practice, Khalsa helped shift the conversation from the old rickets-prevention mindset toward a broader recognition of vitamin D as a foundational hormone.

For more than a decade since, the idea has remained a quiet status marker among those who track biomarkers, longevity protocols, and preventive health—exactly the audience now paying attention to more sophisticated ways of restoring the body’s own production.

A Brand New Regulatory Lane

Solius Pro received 510(k) clearance (K252960) on January 16, 2026, as a Class II medical device under a newly established product code, SGZ (“Ultraviolet Lamp Products”). The indication is deliberately narrow and precise: an over-the-counter light panel intended to stimulate production of vitamin D in people.

That wording matters. Traditional narrow-band UVB devices used in dermatology clinics for psoriasis, eczema, or vitiligo operate at different wavelengths and doses and remain prescription-only. Tanning beds fall under older sunlamp regulations focused on cosmetic tanning. Solius sat in neither category. Its combination of a targeted 293-nanometer LED spectrum, a patent-pending optical skin sensor that calculates a personalized sub-erythemal dose, distance sensing, app-enforced lockouts, and eyewear detection was novel enough that the FDA carved out a distinct regulatory pathway. The result is the first device of its kind cleared for home use without a prescription.

The $23 Million Bet On Precision Sunlight

The clearance and commercial launch arrived together with a $23 million Series A led by Lauder Partners. The financing underscored investor conviction that controlled, personalized UVB could become a measurable health input rather than an afterthought to sunscreen culture. Solius employs roughly two dozen people and has positioned the device for both direct-to-consumer homes and professional wellness or clinical settings. Early demand included more than 1,000 pre-orders before shipping had even begun.

What Makes The Hardware Unique

Physically, Solius Pro is a slim panel (approximately 20 by 24 by 2.5 inches, 7.1 pounds) that hangs on a door or wall and plugs into a standard outlet. A detachable skin-measurement cone and smartphone app guide the user through a brief pigmentation reading; the system then delivers a calibrated dose of UVB concentrated in the vitamin-D action spectrum. A typical session lasts about five minutes once a week. Protective eyewear is required; the software will not run the lights without it and enforces a 24-hour cooldown between treatments.

The company states the targeted spectrum can deliver the vitamin-D–producing benefit of roughly an hour of midday midlatitude sun in those five minutes while exposing the skin to far less total ultraviolet radiation than natural sunlight or conventional phototherapy lamps. Whether that efficiency claim holds up under independent scrutiny remains an open scientific question, but the engineering approach—LED source, real-time skin sensing, and software guardrails—is what enabled the new OTC category.

The Clinical Data And The Oral Comparison

The pivotal evidence is a randomized, sham-controlled trial published in Anticancer Research (Shirvani & Holick, 2025). Adults with vitamin D deficiency or insufficiency who received weekly Solius exposures saw an average 10.2 ng/mL rise in serum 25-hydroxyvitamin D over 21 weeks; the sham group declined 2.3 ng/mL. No serious adverse events were reported.

That trial was not a head-to-head comparison against oral supplementation. Independent literature, however, has repeatedly shown that the two routes are not interchangeable. A 2012 systematic review and meta-analysis in The American Journal of Clinical Nutrition established that vitamin D3 raises serum 25(OH)D more effectively than D2, but it did not address cutaneous versus oral delivery. Solius’s counter is that cutaneous production is self-regulating, avoids gastrointestinal absorption issues, and restores a biological process modern indoor life has largely eliminated. Other controlled studies have found that UVB-generated vitamin D produces different transcriptional profiles in skin and blood, higher tissue storage of the parent compound, and measurable increases in nitric-oxide–related markers that oral D3 does not replicate. One randomized trial comparing high-dose oral D3 with narrow-band UVB found no difference in lipid profiles but clear divergence in immune-pathway signaling. Pig-model work has likewise demonstrated distinct metabolic routing and anti-inflammatory effects when vitamin D is produced in skin rather than ingested.

The Established Role Of Narrowband UVB In Dermatology

It is worth noting that conventional narrowband UVB phototherapy (typically peaking near 311–313 nm) has long been a first-line or adjunctive treatment for several inflammatory skin diseases. Joint guidelines from the American Academy of Dermatology and the National Psoriasis Foundation, along with multiple systematic reviews and meta-analyses published in the Journal of the American Academy of Dermatology and the British Journal of Dermatology, affirm its efficacy for moderate-to-severe plaque psoriasis, as well as for vitiligo, atopic dermatitis, and certain other dermatoses. Solius’s current device operates at a different peak wavelength (~293 nm) optimized for vitamin D synthesis. According to founder and CEO Chris Kiple, however, the company is currently in discussions and early collaborative work with the National Psoriasis Foundation to explore aspects of the Solius technology for dermatologic applications. Any such research would require separate clinical trials and a distinct regulatory pathway beyond the device’s present indication for stimulating vitamin D production.

Practical Realities

What makes Solius quietly radical is not its $2,999 pricetag or its app, but the simple recognition that the human body was never designed to receive its most essential hormone exclusively through a gelatin capsule. For the first time, a medical device has been engineered to restore—with precision, measurement, and regulatory rigor—a biological conversation between skin and light that civilization has spent the last century trying to silence. In an age that has turned sunlight into a controlled hazard and vitamin D into a commodity, the panel hanging on a door represents something almost anachronistic: the decision to trust the body again, only this time with better instruments.

The Larger Question

Solius has forced regulators, investors, and clinicians to confront a simple but consequential distinction: raising serum 25(OH)D with a pill is not identical to restoring the body’s ability to make the hormone under controlled light. By earning a purpose-built FDA product code, securing substantial growth capital, and shipping the first personalized OTC UVB system, the company has opened a new category. Whether that category expands beyond vitamin D stimulation will be determined by larger independent trials and real-world outcomes.

For now, the regulatory fact is clear. The FDA created a lane that did not previously exist and Solius is the first vehicle driving in it.